**Core tip**: We present herein a novel thyroxine-binding globulin (TBG) mutation in exon 1, c.381_382 ins TTGCAGATAGGAAATGCCC (p.Phe135Alafs\*21), which was associated with complete TGB deficiency in a Chinese family. This 19-nucleotide insertion in exon 1 resulted in a frameshift and a premature stop codon at position 155 of the protein coding sequence. TBG deficiency is often misdiagnosed as hypothyroidism. Clinical awareness is needed to correctly diagnose affected individuals and avoid unnecessary treatment. Genomic testing is a method to identify the mutation carriers and provide appropriate genetic counseling for affected individuals.

INTRODUCTION
============

Thyroxine-binding globulin (TBG) is the main thyroid hormone transport protein in humans, carrying approximately 75% of the total thyroxine (TT~4~) and 70% of the total triiodothyronine (TT~3~) present in serum\[[@B1]-[@B3]\]. The human *TBG* gene belongs to the serpin family of genes and is located on the long arm of the X-chromosome (Xq22.2)\[[@B4],[@B5]\]. Abnormalities in TBG are caused by mutations in the *TBG* gene, and demonstrate an X-linked pattern of inheritance\[[@B6]-[@B8]\]. Based on the serum levels of TBG in hemizygotes expressing only the mutant allele, TBG defects are classified as complete TBG deficiency (TBG-CD), partial TBG deficiency (TBG-PD), and TBG excess (TBG-E)\[[@B1]\].

To date, 28 *TBG* mutations that cause TBG-CD have been identified: 7 intron region mutations, 20 exon mutations, and 1 mutation involving both an intron and an exon. These 28 mutations include 14 single nucleotide substitutions, 12 nucleotide deletions, 1 deletion-insertion, and 1 single nucleotide insertion. Additionally, 19 *TBG* gene mutations result in TBG-PD; all of them are single nucleotide substitutions, with 17 in exon regions, 1 in an intron, and 1 in the downstream enhancer region of the *TBG* gene. Furthermore, 3 single nucleotide substitutions in *TBG* have been identified as gene polymorphisms that do not cause changes in TBG levels\[[@B9]-[@B14]\]. As yet, no large insertional mutations that associate with TBG-CD have been reported in *TBG*.

Here, we report a novel *TBG* mutation in exon1, c.381_382 ins TTGCAGATAGGAAATGCCC (p.Phe135Alafs\*21), which was associated with TBG-CD in a Chinese family. This 19-nucleotide insertion in exon 1 resulted in a frameshift and a premature stop codon at position 155 of the protein coding sequence; the mutation is termed TBG-CDC. The proband and his brother are hemizygous for the mutation, and manifested the TBG-CD phenotype. The proband's mother is heterozygous for this mutation, but displayed the same TBG-CD phenotype as her affected sons. The proband's father has a single nucleotide substitution in exon 3, c.909G\>T (p.Leu303Phe), which is known as *TBG*-Poly (L283F). The proband's father had low TT~4~ and TT~3~, but a normal amount of thyrotropin (TSH), and his serum TBG level was between normal and affected hemizygous, which is inconsistent with previous reports that this polymorphism causes no changes in TBG levels.

CASE PRESENTATION
=================

Chief complaints
----------------

A 46-year-old Chinese man had a health examination at a local hospital. He had normal free thyroxine (FT~4~), free triiodothyronine (FT~3~), and TSH, but low TT~4~ and TT~3~. The patient was then referred to our hospital for additional diagnosis.

History of present illness
--------------------------

The patient underwent physical examination a month ago and abnormal thyroid function was found.

History of past illness
-----------------------

The patient had a free previous medical history.

Physical examination
--------------------

The patient's thyroid gland was normal, without nodules, as measured by thyroid gland ultrasound. The patient denied symptoms of weakness, drowsiness, and intolerance to cold.

Laboratory examinations
-----------------------

Upon re-evaluation of the patient's thyroid function, we detected low serum TT~4~ and TT~3~ levels, normal FT~4~, FT~3~, and TSH levels, and undetectable serum TBG (the lower limit of detection of the assay was 3.5 μg/mL; normal range: 14--31 μg/mL).

Further diagnostic work-up
--------------------------

To find out if other people in the proband\'s family have similar performance, blood samples were obtained from the patient's family members, including his paternal grandfather, parents, younger brother, and nephew. To identify the prevalence of the *TBG*-Poly (L283F) variant in Chinese men, serum and whole blood samples were obtained from 117 unrelated Han Chinese men from northeastern China.

Serum TT~4~, TT~3~, FT~3~, FT~4~, TSH, thyroglobulin antibodies (TgAb), and thyroperoxidase antibodies (TPOAb) were measured using electro-chemiluminescence immunoassays performed on a Cobas Elesys 601 instrument. TT~4~, TT~3~, FT~3~, FT~4~, TSH, TgAb, TPOAb were analyzed using the competition principle, and TSH using the sandwich principle (Catalog number: 26047103 for TSH, 23816601 for TT~3~, 25785701 for FT~3~, 24807703 for TT~4~, 24682503 for FT~4~, 22084502 for TPOAb, and 23015003 for TgAb, Roche Diagnostics GmbH, Mannheim, Germany). Serum TBG and thyroglobulin (Tg) were measured using a solid--phase, competitive chemiluminescent enzyme immunoassay on an Immulite 2000 Xpi instrument (Catalog number: L2KTB2 for TBG and L2KTY2 for Tg, Siemens Healthcare Diagnostics Products limited, United Kingdom). Genomic DNA was isolated from peripheral blood using a DNA Kit (TIANGEN, Beijing, China), and targeted sequences were amplified by PCR. Gene regions including exons 1--4 of the *TBG* gene and intron-exon boundaries were sequenced (3730XL; Applied Biosystems, Carlsbad, California). Quantitative PCR high-resolution melting curve analysis was used to screen the *TBG*-Poly (L283F) variant among 117 Chinese men; the results were verified by direct DNA sequencing. The primers used in PCR amplification and sequencing are shown in Table [1](#T1){ref-type="table"}.

###### 

Primers used in PCR amplification and sequencing

  **Primer ID**          **Primer sequence**
  ---------------------- --------------------------
  Sequencing             
  Exon 1                 
  SERPINA7-F             AGAGAAACCCCTGCTCAG
  SERPINA7-R             TTTCCTGGACTCATTCACAG
  Exon 2                 
  SERPINA7-F             GGTACCTAACTCTGTGGTGA
  SERPINA7-R             CATAGCTGTTGGGTAGTTCA
  Exon 3                 
  SERPINA7-F             TGGTTATCAATACTCAGGGAAG
  SERPINA7-R             TCTAGCTTAGGAGGAGTCAC
  Exon 4                 
  SERPINA7-F             ACTACATTTAGCAGAGGAAAC
  SERPINA7-R             CAAAGTTCAGCCAGGGTT
  qPCR-HRM               
  *TBG*-Poly of exon 3   
  Forward primer         AAAGTGTGGCTCCAAGGTCA
  Reverse primer         GGTGATTGCCATGTGTTCCC
  Sanger sequencing      
  *TBG*-Poly of exon 3   
  Forward primer         AGAGAGAAGGAGAGAATCATAAGC
  Reverse primer         TGGAAAGTTTCAGACCATTGTC
  *TBG*-Xq22G\>A         
  Forward primer         GTTGGGAAACTGGAAGGAGA
  Reverse primer         AGAGGTGGAAAGGGGAAGAG

Gene regions including exons 1-4 of the *TBG* gene and intron-exon boundaries were sequenced. Quantitative PCR high-resolution melting (HRM) curve analysis was adopted to detect the *TBG*-Poly (L283F) variant. Sanger sequencing was used to confirm the mutation identified by HRM and to detect the *TBG*-Xq22G\>A mutation. qPCR-HRM: Quantitative PCR high-resolution melting; *TBG*-Poly: *TBG* polymorphism (L283F).

The pedigrees and results of the thyroid function tests (TFTs) of the family members are shown in Figure [1](#F1){ref-type="fig"}. The proband (III-3), his brother (III-2), and his mother (II-1) had low serum TT~4~ and TT~3~ levels but normal TSH concentrations, and serum TBG was undetectable, which is characteristic of TBG-CD. The proband's father (II-2) had low TT~4~ and TT~3~, but normal TSH; his serum TBG level was between normal and affected hemizygous (Figure [1](#F1){ref-type="fig"}), which indicated TBG-PD. The proband's grandfather (I-2) and nephew (IV-1) had normal TFTs. All family members had normal thyroglobulin (Tg), TgAb, and TPOAb levels.

![Pedigree showing the genotype and thyroid function test results of the proband's family. The results of thyroid function tests are aligned below each individual. Abnormal values are indicated in bold. Low values are marked with a downward arrow, and undetectable values are marked in red.](WJCC-7-3887-g001){#F1}

Two mutations in the *TBG* gene were identified in this Chinese family. One, a novel mutation, was identified in the index III-3, III-2, and II-1. This mutation is a 19-nucleotide insertion, occurring between cDNA positions 381 and 382 (c.381_382insTTGCAGATAGGAAATGCCC) in exon 1. This mutation changes the phenylalanine at codon 135 to alanine, following which there are 19 amino acids and then an early termination codon at position 155, leading to premature termination of TBG (Figure [2A](#F2){ref-type="fig"}). This mutation results in a truncated protein containing only the first 134 amino acids; in comparison, the wild-type TBG protein (TBG-C) is 395 amino acids long, excluding the 20 amino acid signal peptide. As expected, the III-3 and III-2 are hemizygous for the *TBG* mutation, while II-1 is heterozygous, demonstrating that the mutation follows a pattern of X-linked inheritance.

![Schematic diagram of the DNA sequence for a portion of exons 1 and 3 of the *TBG* gene. The exons 1--4 region of the *TBG* gene and intron-exon boundaries were sequenced. For the variant names, the GenBank reference sequences NM_000354.5 and NP_000345.2 are used. Nucleotide numbering reflects cDNA numbering, with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to HGVS guidelines (<http://varnomen.hgvs.org/>). The initiation codon is codon 1. Panel A displays a portion of exon 1 of the *TBG* gene showing the location of the insertional mutation. The upper part of the schematic diagram is the normal DNA sequence for this portion of exon 1. The middle and lower parts of the schematic diagram indicate the abnormal sequences of a portion of exon 1 of the *TBG* gene in two hemizygous sons (III-2 and III-3) and the heterozygous mother (II-1), respectively. A 19-nucleotide sequence was inserted between cDNA positions 381 and 382 (c.381_382insTTGCAGATAGGAAATG CCC) in exon 1. This mutation changes the phenylalanine at codon 135 to alanine and then encodes 19 amino acids, followed by an early termination codon at position 155, leading to premature termination of the thyroxine-binding globulin protein. The arrow indicates the start point of this mutation. The insertion sequence is located between the dotted lines. Panel B shows a schematic of a single nucleotide mutation in exon 3 of the *TBG* gene. A single nucleotide mutation (TTG→TTT) at codon 909 was identified in the proband's father (II-2), but not in the other family members.](WJCC-7-3887-g002){#F2}

The other *TBG* mutation is a single nucleotide substitution (TTG→TTT) in codon 303 in exon 3 (p.Leu303Phe), which was identified in the II-2 (Figure [2B](#F2){ref-type="fig"}). This variant was previously known as *TBG* polymorphism, *TBG*-Poly (L283F). The II-2 carried the *TBG*-Poly (L283F) polymorphism and presented with TBG-PD. He had low TT~4~ and TT~3~ levels, with his serum TBG levels falling between normal and affected hemizygous levels (Figure [1](#F1){ref-type="fig"}).

The frequency of the *TBG*-Poly allele among the 117 unrelated Han Chinese men was found to be 21.37%.

DISCUSSION
==========

In the present study, we identify a novel mutation, named TBG-CDC, in *TBG* (p.Phe135Alafs\*21) from a Chinese family. This mutation is a 19-nucleotide insertion, located between cDNA positions 381 and 382 in exon 1, and is the first reported large nucleotide fragment insertional mutation of the *TBG* gene that results in TBG-CD.

This mutation resulted in a truncated protein that contained only the first 134 of the 395 amino acids of the mature TBG-C, and lacked 66% of the carboxyl terminal amino acids. The carboxyl terminus of TBG is important for intracellular transport and protein synthesis\[[@B15]\]. We used Mutation Taster software to predict the disease-causing potential of this mutation\[[@B16]\]. The prediction suggested that the truncated TBG protein lost two glycosylation sites (at positions 165 and 253), and two thyroxine binding sites (at positions 293 and 398). Glycosylation plays an important role in the processing, folding, and secretion of TBG, and the thyroxine binding sites of TBG are associated with the transport of thyroid hormone in blood\[[@B17]-[@B19]\]; we therefore speculate that this truncation of TBG may lead to TBG-CD, and may result in a reduction in TT~3~ and TT~4~ levels. However, the mechanism for the failure to detect immunoreactive TBG in the serum of these patients harboring this mutation remains unknown. We speculate that three reasons may be concerned. The first one may be the impaired synthesis of the truncated TBG proteins. The 19-nucleotide insertion in exon 1 is supposed to affect the transcription or the translation of TBG, leading to the failure of synthesis of mutant TBG. The second one may be the impaired secretion of the truncated TBG proteins. Most of the truncated TBG molecules previously reported were not secreted\[[@B20]-[@B22]\]. They remained in the rough endoplasmic reticulum and were rapidly degraded within the cells, or had impaired intracellular transport in the blood. And the last reason may be associated with the TBG antibodies used in the present study, which can only bind to the truncated region, but not to the non-truncated region, and hence results in no detection of serum TBG.

Since inherited TBG defects follow an X-linked pattern, TBG-CD is fully manifested in hemizygous males but only partially in heterozygous females\[[@B1]\]. However, the TBG-CD phenotype has been reported in two heterozygous females with selective inactivation of the X-chromosome carrying the normal *TBG* alleles\[[@B23]\], and in two females with XO Turner's syndrome\[[@B24],[@B25]\].

In the family we studied, the II-1 also manifested TBG-CD, but the molecular basis for her TBG-CD remains unclear. The proband's mother has normal stature and fertility, and therefore XO Turner's syndrome is unlikely, although the condition cannot be ruled out without additional investigation. We speculate that selective inactivation of the X-chromosome containing the *TBG*-C allele may be associated with her phenotype presentation.

The *TBG*-Poly (L283F) variation is a common polymorphism, with high prevalence in different races and regions, including 16% of French Canadian males\[[@B26]\], 50% of Australian Aboriginal males\[[@B27]\], 20% of the Japanese population\[[@B28]\], 31% of the Han Chinese population in Taiwan\[[@B29]\], and 21.37% of Chinese men in northeastern China. Previous studies have reported that *TBG*-Poly (L283F) causes no changes in biological properties\[[@B27]\]. It is worth noting that the majority of complete TBG defects are associated with nonsense mutations that produce truncated protein, or with missense mutations associated with the presence of the L283F polymorphism (*TBG*-Poly)\[[@B26],[@B29]\]. In the present study, we report that the II-2 presented with the TBG--PD phenotype. Whether the *TBG*-Poly (L283F) is responsible for lower TBG levels as well as lower levels of TT~3~ and TT~4~ remains unclear. Ferrara et al\[[@B12]\] previously reported a mutation in the *TBG* gene enhancer region, the Xq22G\>A mutation, which is located 20 kb downstream of the *TBG* gene; this mutation has been associated with the TBG-PD phenotype. However, the Xq22G\>A mutation was not detected in the II-2. Since only *TBG* coding regions and adjacent intron regions were sequenced in the present study, abnormalities in other transcriptional regulatory elements associated with this gene might be involved in the variable phenotypes seen in the Chinese male with *TBG*-Poly (L283F); these possibilities merit further investigation.

TBG deficiency may produce alterations in total thyroid hormone concentration in serum, whereas free THs remain unchanged. So TBG deficiency is often misdiagnosed as hypothyroidism. Clinical awareness is needed to correctly diagnose affected individuals and avoid inappropriate treatment. Genomic testing is a method to identify the mutation carriers and provide appropriate genetic counseling for affected individual\[[@B29],[@B30]\].

CONCLUSION
==========

In conclusion, a novel *TBG* mutation, p.Phe135Alafs\*21, was identified in a Chinese family. This mutation is a 19-nucleotide insertion in exon 1, produces truncated TBG protein, and is termed "TBG-CDC". The fact that the proband's father had the *TBG*-Poly (L283F) variant and presented as TBG-PD merits further investigation. The allelic frequency of *TBG*-Poly (L283F) was found to be 21.37% in 117 unrelated Chinese males in northeastern China.
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